Redox Pharmaceutical Corporation

Greenvale, NY 11548

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $398K
First Award Date 09/30/93
Most Recent Award Date 07/01/00

Key Personnel

Last Name Name Awards Contact
Dori Zvi Dori 1
Burger Richard M Burger 5
Gershon David Gershon 1

7 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/00 - 06/30/02

DESCRIPTION (Adapted from the application): The applicant~s new organometallic antiviral, CTC 96 (Doxovir (TM)) has demonstrated activity against herpes simplex virus type 1 (HSV-1) in cell culture and animal models of ocular disease. The closely related HSV-2, which is the cause of 45 million cases of genital herpes infection in the U.S. alone,...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/99 - 06/30/00

DESCRIPTION (Adapted from the application): The applicant~s new organometallic antiviral, CTC 96 (Doxovir (TM)) has demonstrated activity against herpes simplex virus type 1 (HSV-1) in cell culture and animal models of ocular disease. The closely related HSV-2, which is the cause of 45 million cases of genital herpes infection in the U.S. alone,...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/98 - 02/28/99

Redox Pharmaceutical Corporations's new antiviral and anti- inflammatory metallo-organic compound, CTC 96 (DoxovirTM) has demonstrated activity against herpes simplex virus type 1 (HSV-1) in cell culture and animal models of ocular disease. The closely related HSV-2, which is the cause of 45 million cases of ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/22/97 - 08/31/98

Redox Pharmaceutical Corporation's new antiviral and anti-inflammatory organometallic compound, CTC 96 (DoxovirTM) has demonstrated activity against herpes simplex virus (HSV) type-1 in cell culture and animal models of human ocular disease. The closely related HSV-2), which is the cause of millions and c...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/97 - 08/31/99

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/96 - 08/31/97

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/93 - 03/31/95
PI: Zvi Dori

HSV-l is the major infectious cause of corneal blindness in the United States. Redox has synthesized transition metal complexes (CTC compounds) exhibiting potent in vitro activity against herpes group viruses. Significantly, the mode of action of these novel compounds differs from currently available antiviral nucleoside analogs. One CTC compou...